Drug Evaluation in Angina Pectoris
Gianluigi Ardissino · Lionel H. Opie · Stefano Savonitto
2012-ж. дек. · Developments in Cardiovascular Medicine 158-китеп · Springer Science & Business Media
Электрондук китеп
262
Барактар
reportРейтинг жана сын-пикирлер текшерилген жок Кеңири маалымат
Учкай маалымат
Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris. Drug Evaluation in Angina Pectoris has two fundamental aims: the first is to review the methodological aspects of drug evaluation in stable and unstable angina pectoris; the second is to provide a logical and methodological background for future studies aimed at assessing the ability of medical treatment to improve prognosis.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Бул электрондук китепти баалаңыз
Оюңуз менен бөлүшүп коюңуз.
Окуу маалыматы
Смартфондор жана планшеттер
Android жана iPad/iPhone үчүн Google Play Китептер колдонмосун орнотуңуз. Ал автоматтык түрдө аккаунтуңуз менен шайкештелип, кайда болбоңуз, онлайнда же оффлайнда окуу мүмкүнчүлүгүн берет.
Ноутбуктар жана компьютерлер
Google Play'ден сатылып алынган аудиокитептерди компьютериңиздин веб браузеринен уга аласыз.
eReaders жана башка түзмөктөр
Kobo eReaders сыяктуу электрондук сыя түзмөктөрүнөн окуу үчүн, файлды жүктөп алып, аны түзмөгүңүзгө өткөрүшүңүз керек. Файлдарды колдоого алынган eReaders'ке өткөрүү үчүн Жардам борборунун нускамаларын аткарыңыз.
